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PHeart Rhythm Disorders
he Impact of Implantable Cardioverter-
efibrillator Therapy on Survival in
utosomal-Dominant Arrhythmogenic
ight Ventricular Cardiomyopathy (ARVD5)
athy A. Hodgkinson, MSC,*† Patrick S. Parfrey, MD, FRCPC, FACP,* Anne S. Bassett, MD, FRCPC,†‡
hristine Kupprion, MD,§ Jörg Drenckhahn, MD,§ Mark W. Norman, MD, MRCP,§
udwig Thierfelder, MD,§ Susan N. Stuckless, MSC,* Elizabeth L. Dicks, MSC,*
illiam J. McKenna, MD, FRCP, Sean P. Connors, MD, DPHIL, FRCPC¶
t. John’s and Toronto, Canada; Berlin, Germany; and London, England
OBJECTIVES We sought to determine the impact of implantable cardioverter-defibrillator (ICD) therapy
in patients with familial arrhythmogenic right ventricular cardiomyopathy (ARVC).
BACKGROUND Arrhythmogenic right ventricular cardiomyopathy is a cause of sudden cardiac death, which
may be prevented by ICD.
METHODS We studied 11 families in which a 3p25 deoxyribonucleic acid (DNA) haplotype at locus
ARVD5 segregated with disease and compared mortality in subjects who received an ICD
with that in control subjects who were matched for age, gender, ARVC status, and family.
Subjects (n  367) at 50% a priori risk of inheriting ARVC were classified as high risk (HR)
(n  197), low risk (n  92), or unknown (n  78) on the basis of clinical events, DNA
haplotyping, and/or pedigree position. Forty-eight HR subjects (30 males, [median age 32
years] and 18 females [median age 41 years]) were followed after ICD (secondary to
ventricular tachycardia [VT] in 27%). Survival was compared with 58 HR control subjects
who were alive at the same age to-the-day at which the ICD subject received the device.
RESULTS In the HR group, 50% of males were dead by 39 years and females by 71 years: relative risk
of death was 5.1 (95% confidence interval 3 to 8.5) for males. The five-year mortality rate
after ICD in males was zero compared with 28% in control subjects (p  0.009). Within five
years, the ICD fired for VT in 70% and for VT 240 beats/min in 30%, with no difference
in discharge rate when analyzed by ICD indication.
CONCLUSIONS The unknown mutation at the ARVD5 locus causing ARVC results in high mortality. Risk
stratification using genetic haplotyping and ICD therapy produced improved survival for
males. (J Am Coll Cardiol 2005;45:400–8) © 2005 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.068Foundation
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dreatment of ventricular tachyarrhythmias, which often
ause sudden cardiac death (SCD), includes antiarrhythmic
See page 409
rugs and implantable cardioverter-defibrillator (ICD) ther-
py. Several randomized control trials have compared these
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ccepted August 9, 2004.reatment modalities (1–4) and showed that antiarrhythmic
edications have limited effectiveness (5). Therefore, ICD
herapy often is considered to be the treatment of choice for
entricular tachyarrhythmias (6). In addition, it is consid-
red safe; rare complications include infections (7), surgical
omplications (8), electrode problems (9), and inappropriate
hocks (10).
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
s a cause of SCD, usually due to tachyarrhythmias (11), for
hich ICD therapy may be effective. Arrhythmogenic right
entricular cardiomyopathy may be a significant cause of
CD in young adults in the U.S. (12) and Italy (13),
lthough its true prevalence is unknown (14). Diagnostic
riteria are determined on the basis of clinical, structural,
nd functional features, with the gold standard for diagnosis
eing the presence of fat and fibrous tissue on cardiac biopsy
r autopsy (15–17). However, antemortem diagnosis is
ifficult despite investigations, including 12-lead electrocar-
iogram (ECG), signal-averaged electrocardiogram
SAECG), echocardiography, magnetic resonance imaging
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February 1, 2005:400–8 ICD Improves Survival in Homogeneous ARVCMRI), and Holter monitoring (HM). These tests are
onspecific, particularly as the true penetrance of the disease
s not clear and variable expression is present both between
nd within families (15).
Arrhythmogenic right ventricular cardiomyopathy is rec-
gnized to be familial (15,18–23) in an estimated 30% of
ases (17,24). However, comprehensive assessments of ex-
ended family trees rarely are documented (25), and familial
ases are likely underrecognized (26). Known causes of
utosomal-dominant ARVC include mutations in the car-
iac ryanodine receptor (RYR2) (27,28) and desmoplakin
29) genes. Other autosomal-dominant ARVC loci include
egions on chromosomes 2 (30), 3 (31), 10 (32,33), and 14
34,35). It is clear that ARVC is a genetically heterogeneous
roup of diseases with phenotypic overlap (36). The number
f ARVC subjects in previous studies defined by genotype is
mall (27,29,30,32–35,37–41).
Abbreviations and Acronyms
ARVC  arrhythmogenic right ventricular
cardiomyopathy
ARVD  arrhythmogenic right ventricular dysplasia
ARVD5  the locus for the mutation causing ARVC on
chromosome 3p25
ECG  electrocardiogram
HM  Holter monitoring
HR  high risk
ICD  implantable cardioverter-defibrillator
LR  low risk
LVE  left ventricular enlargement
MRI  magnetic resonance imaging
SAECG  signal-averaged electrocardiogram
SCD  sudden cardiac death
UK  unknown
VT  ventricular tachycardiaigure 1. Part of one of 11 autosomal-dominant families with arrhythmogenic
t high risk (n  197), low risk (n  92), and unknown (n  78) status.A Newfoundland family with autosomal-dominant
RVC was reported in 1988 (42). The diagnosis of ARVC
as made after postmortem documentation of fat and fiber
n the myocardium and of clinical features, fulfilling pub-
ished criteria (17). In this family, ARVC was linked
ubsequently to the short arm of chromosome 3 encompass-
ng a critical region of 9.3cM (31) at 3p25 (ARVD5).
ubsequently, 10 additional families with ARVC were
tudied, and the critical region was reduced to 2cM, at
hich locus the identical set of DNA markers (haplotype)
osegregates with ARVC. This segregation with disease
cross generations suggests a common founder in these 11
ewfoundland families (43) and provides by far the largest
roup of subjects with ARVC defined by genotype. There-
ore, risk stratification of subjects by ARVC status is feasible
n these families on the basis of family history, clinical
istory, and genetic haplotype (linkage analysis) data (a
ethodology used clinically in several genetic disorders
efore determining an underlying causative mutation)
44,45).
Previous studies of ICD therapy in patients with ARVC
etrospectively assessed efficacy in individual patients in the
bsence of appropriate controls (9,46–49). We investigated
ortality after the implantation of ICDs in 48 high-risk
HR) subjects from 11 families with an autosomal-
ominant homogeneous form of ARVC linked to 3p25 and
ompared mortality with that in HR control subjects, who
ere matched for age and gender, from the same families.
ETHODS
ample population. Thirty-five families were referred to
he provincial genetics program because of SCD and a
amily history of cardiomyopathy. Eleven were determinedright ventricular cardiomyopathy linked to 3p25 showing family members
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ICD Improves Survival in Homogeneous ARVC February 1, 2005:400–8o have autosomal-dominant ARVC (Fig. 1) on the basis of
stablished histopathologic, clinical, and genetic criteria
17). One of these families was the original family in which
he linkage to chromosome 3 was defined (31,50), and 10
ther families were found to be linked to the same region.
ive hundred fifty-one individuals from extant and ancestral
enerations from these 11 families who were born at a priori
0% pedigree risk (ARVC-affected individuals and their
rst-degree relatives) were identified. To minimize the
ffects of ascertainment and referral bias, 367 subjects (212
ale, 155 female) from “well-ascertained” sibships were
tudied. Well-ascertained sibships were defined as those
here 50% of siblings were known to be at high or low
isk of ARVC as determined on the basis of clinical,
edigree, and/or haplotype data. High risk was defined as
ocumented sustained ventricular tachycardia (VT) or
therwise-unexplained SCD 50 years of age, the presence
f a HR DNA haplotype, and/or obligate carrier status
affected offspring and parent) by pedigree analysis. Subjects
ould be defined based on any or all of these criteria for HR
tatus. Low risk (LR) was defined as LR DNA haplotype.
therwise, subjects were considered unknown risk status
UK). The terms HR and LR are used because the common
isease haplotype is assumed to cosegregate with the as-yet
nknown disease-causing mutation.
Consent for analysis of past and current cardiology
ecords and for DNA analysis was obtained from each
ubject (or surrogate) in compliance with the Human
nvestigation Committee requirements of the Health Care
orporation of St. John’s. All available clinical records and
utopsy reports were obtained.
A cardiomyopathy genetics research clinic was initiated in
998. Serial data (retrospective and prospective) on subjects
t a priori 50% risk were collected (including clinical events,
2-lead ECG, SAECG, HM echocardiography, and MRI),
nd subjects were offered genetic haplotype analysis. Im-
lantable cardioverter-defibrillator therapy was offered to
hese subjects on the basis of a HR DNA haplotype and an
bnormal clinical test that was compatible with ARVC (n
5 males and 18 females). None of these subjects had
ocumented VT. Two more males received an ICD after a
R DNA result alone. Seven males before 1998 and six
ales who received implants in other North American
enters had ICDs because of sustained VT that required
ardioversion. No individual to date has declined an ICD,
lthough one HR subject refused follow-up and died sud-
enly at 31 years of age. One subject died six weeks after
rst attending clinic during clinical work-up, and prior to
eceipt of a HR haplotype result. Thus, we report on the
utcome of 30 male and 18 female subjects with ICDs, 73%
f which were implanted for the primary prevention of VT.
All ICD recipients were followed biannually, at which
ime the ICD was examined. After confirmation of sus-
ained ventricular tachyarrhythmias, verified by the stored
lectrocardiograms after ICD discharge, time to first appro-
riate discharge for documented VT was recorded, as was lime to first VT 240 beats/min. A rate of 240 beats/min
as chosen to delineate potentially fatal arrhythmias (in the
bsence of the ICD) from probable nonfatal arrhythmias
51,52). Implantable cardioverter-defibrillator discharge was
ot included if it occurred within one week of the implant
ate. Inappropriate ICD discharge was defined as atrial
brillation, sinus tachycardia, or non-sustained VT.
aplotype analysis. Of 367 subjects from well ascertained
ibships, 201 (55%) had a venous blood sample collected.
NA was extracted from peripheral lymphocytes as previ-
usly described (53). For each polymorphic short tandem
epeat DNA marker, fluorescent-labeled primers were used
o amplify di-, tri-, or tetra nucleotide repeats by the
olymerase chain reaction, and fragments were analyzed by
apillary gel electrophoresis by the use of an ABI 310
enetic analyzer (Applied Biosystems, Foster City, Califor-
ia). The presence or absence of the 2cMHR haplotype was
etermined for each family member assessed.
tudy design. Age to death was determined in the initial
ohort of 197 HR, 92 LR, and 78 UK subjects from the 11
RVC families, with censoring at last follow-up or at time of
CD implantation. Survival after ICD was determined and
ompared with that of control subjects after entry to the study.
or each ICD subject, control HR subjects were selected who
id not receive an ICD, were the same gender, were alive at the
ge to-the-day at which the ICD subject received the ICD,
nd were first- or second-degree relatives of the ICD subject.
ll available first- and second-degree relatives meeting these
riteria were used as controls (n  40; 69%). If there were no
ge/gender-matched first- or second-degree relatives, one
hird- or fourth-degree relative was used (n 11; 19%). In the
bsence of any appropriate relatives, one age- and gender-
atched control subject from a family in the same geographical
egion was used (n  7; 12%).
The primary outcome was age at death defined to the day.
econdary outcomes were time to initial appropriate ICD
evice discharge for sustained VT and time to first VT
240 beats/min. Time to first appropriate discharge was
ompared in those who had ICD for primary versus sec-
ndary prophylaxis and in those with versus those without
eft ventricular enlargement (LVE) based on the Henry
alculations defined as 2 SD above the mean for LVE
112%) (54,55).
tatistical analysis. We used version 11.5 of the SPSS
tatistics package for statistical analyses of clinical tests
SPSS, Chicago, Illinois). Categorical data were compared
y the chi-square test. A p value of 0.05 was considered
ignificant. Survival was calculated according to the Kaplan-
eier product limit method. Relative risk was calculated
sing Cox’s regression model. Follow-up continued until
eath or June 3, 2003.
ESULTS
n affected-only linkage analysis was performed in the first
arge Newfoundland family described (42). Of 17 affected
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February 1, 2005:400–8 ICD Improves Survival in Homogeneous ARVCndividuals who had DNA samples available for molecular
nalysis, 11 manifested symptomatic sustained VT before
hey were 50 years of age, 1 demonstrated ARVC pathology
t autopsy, and 5 were obligate ARVC disease gene carriers.
wenty-one deceased family members who transmitted
RVC through five generations also were considered obli-
ate carriers. Linkage of disease to 3p25 was confirmed with
maximum multipoint logarithm of the odds score of 9.3 at
3S1585. Analysis of eight markers allowed the construc-
ion of a chromosome 3p25 HR haplotype with D3S3610-
ibulin2-D3S2385-D3S1585-D3S1554-708d1CA-
16A10CA-D3S3613 ordered from telomere to centromere
hared by all affected family members. The HR haplotype
lso was identified in all affected subjects from 10 other
amilies with autosomal-dominant ARVC.
As shown in Table 1, 197 (54%) of the well-ascertained
ample was designated HR. The method of determining
isk status in men was approximately evenly divided between
edigree position (33%), DNA haplotype (31%), and sub-
ects who were 50 years of age with SCD or VT (36%).
ew women were diagnosed as HR because they had SCD
r VT. Two hundred seven (56%) of the 367 subjects were
orn after 1950. Most HR male subjects had died, in
omparison with approximately one quarter of HR female
ubjects, and 76% of male and 39% of female deaths were
ue to SCD. Only four LR subjects died, which is compat-
ble with survival being necessary to obtain a blood sample
or DNA tests (Table 1). It is likely that most of those with
K status are in fact LR.
verall mortality in the ARVC population. Median
urvival in HR males (n  123) was 39 years (95%
onfidence interval [CI] 36 to 42), in LR males (n  46)
as 76 years (95% CI 76), and in unknown males (n  43)
as 67 years (95% CI 63 to 71). Median survival for HR
emales (n  74) was 71 years (95% CI 64 to 78), for LR
emales (n  46), the median age could not be computed
ecause of the lack of events, and UK females (n  35) was
3 years (95% CI 51 to 115 years). The mortality rate was
ignificantly greater in HR than LR males (p  0.00001)
able 1. Demographic Data, Method of Risk Determination, and
nheriting ARVC, From 11 Families Linked to 3p25: Defined by
High Risk (n  197)
Male
(n  123)
Female
(n  74)
n % n %
orn 1950 (n  160) 61 50 32 43
orn 1950 (n  207) 62 50 42 57
ethods of diagnosis
Obligate carrier (OC) 41 33 30 41
DNA haplotype 38 31 41 55
Clinical event (SCD or VT) 44 36 3 4
ead 82 67 18 24
CD 62 50 7 9
RVC  arrhythmogenic right ventricular cardiomyopathy; SCD  sudden cardiacnd HR than LR females (p  0.01). The youngest age at
a
teath in HR males was 19 years, and the oldest was 72
ears. In HR females, the respective ages were 37 and 88
ears. Female HR subjects survived significantly longer than
ale HR subjects (p  0.00001) (Fig. 2). The relative risk
f death for males compared with females in the HR group
as 5.1 (95% CI 3 to 8.5). We also assessed mortality in
ubjects born before and after 1950 to take into account
ossible effects of differences in risk status determination:
esults remained the same (data not shown).
ubjects studied. There were 30 males who received ICDs
t median age of 33 years (range, 15 to 51 years) and 18
emales at median age of 42 years (range, 22 to 56 years).
mplantable cardioverter-defibrillators were implanted in 17
ales and 18 females in the absence of documented VT
primary prophylaxis) and in the remaining 13 males after
T (secondary prophylaxis). Fifty-eight control subjects
onsisted of 36 males whose median age at study entry was
3 years (range, 15 to 51 years) and 22 female subjects
hose median age at study entry was 39 years (range, 22 to
6 years) (Table 2).
se of Death in 367 Subjects at an a Priori 50% Risk of
VC Risk Status
Low Risk (n  92) Unknown (n  78)
Male
(n  46)
Female
(n  46)
Male
(n  43)
Female
(n  35)
n % n % n % n %
10 22 13 28 27 63 17 49
36 78 33 72 16 37 18 51
— — — — — — — —
46 100 46 100 — — — —
— — — — — — — —
1 2 3 6 19 44 11 31
— — — — 1 2 — —
; VT  ventricular tachycardia.
igure 2. Time to death or last follow-up (censored) in high-risk malesCau
ARnd females with arrhythmogenic right ventricular cardiomyopathy linked
o 3p25.
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ICD Improves Survival in Homogeneous ARVC February 1, 2005:400–8Most of the ICD subjects had their risk status defined by
NA haplotype and were born after 1950. In contrast, 36 of
8 of the control subjects were born before 1950 and had
isk status defined by pedigree position. The age at entering
he study was the same in the control group as the age of
eceipt of ICD, reflecting the matching strategy. There were
o statistically significant differences between ICD cases
nd control subjects in medication profile, the presence of
yncope or chest pain, or abnormalities on SAECG, ECG,
M, or MRI. However, a significantly greater proportion
f cases had documented palpitation and presyncope than
able 2. Demographic Data and Method of Risk Determination
8 Matched Control Subjects From 11 Families With ARVC Li
Demographic Parameters
ICD Cohort
Males
(n  30)
Females
(n  18)
n % n %
orn 1950 2 6 1 5
orn 1950 28 93 17 95
ethods of diagnosis
Obligate carrier (OC) 4 13 4 50
DNA haplotype 22 74 14 39
Clinical event (SCD or VT) 4 13 0 0
ean age at entry (yrs) 33.3 40.3
edian age at entry (yrs) 32.9 42
tandard deviation (yrs) 9.8 9.0
Chi-square with 1 df for ICD MF vs. control MF.
ARVC  arrhythmogenic right ventricular cardiomyopathy; ICD  implantable
able 3. Clinical Manifestations of ARVC in 48 Subjects at Hig
rom 11 Families With ARVC Linked to 3p25
ICD Cohort (n  48)
No. With
Manifestation
No. With
Documentation
ntiarrhythmic medications*
Class 1 10 44
Sotalol 13 44
Amiodarone 11 44
ymptoms
Palpitations 35 44
Presyncope 29 44
Syncope 15 44
Chest pain 14 44
Heart failure 6 47
bnormal clinical tests†
12-lead ECG‡ 33 48
SAECG§ 17 31
Echocardiogram¶ 24 42
Holter monitor 33 42
MRI** 4 23
Catheterization†† 0 18
Autopsy‡‡ 0 0
Class 1 medications: mexilitine, propafenone, procainamide, quinidine, and phenytoin
ecause they never visited a doctor. †Abnormalities on clinical tests. ‡Electrocardiogr
r presence of PVCs (17, 56). §Signal-averaged ECG (SAECG): 115 ms QRS dur
ilatation, focal or global hypokinesis, or akinesis of any cardiac wall (17, 57–59). Hol
esonance imaging (MRI): evidence of fatty/fibrous infiltrate or ventricular thinning (6
f fat and fiber in the myocardium (17,64).
ARVC  arrhythmogenic right ventricular cardiomyopathy; ICD  implantable cardioid the controls (Table 3). The abnormalities noted on
linical testing are listed in Table 3 (17,54,56–64).
ortality after ICD. The male ICD group was followed
or a median of 2.6 years (from 3 weeks to 12.8 years) and
he control group for a median of 9.5 years (from 4.5
onths to 31 years). There were no deaths in the ICD
roup. Three subjects went on to successfully receive a heart
ransplant after several years (range, 2 to 10 years) of ICD
herapy. Indications for transplant included increasing heart
ailure as a secondary consequence of cardiomyopathy and
ntractable VT. One subject in the control group received a
RVC in 48 Subjects at High Risk Who Received an ICD and
to 3p25
Control Cohort
ICD
Cohort
MF
48
Control
Cohort
MF
58 p Value*
Males
n  36)
Females
(n  22)
% n %
69 19 86 3 44 0.0001
31 3 14 45 14
51 17 49 8 35 0.0001
50 5 50 36 10 0.0001
10 0 0 4 13 0.05
32.2 40 ns
32.7 39.2 ns
9.6 9.5 ns
verter-defibrillator; SCD  sudden cardiac death; VT  ventricular tachycardia.
k Who Received an ICD and 58 Matched Control Subjects
Control Cohort (n  58)
Chi-Square 1 df,
p Value
No. With
Manifestation
No. With
Documentation %
11 42 26 ns
6 31 13 ns
5 30 17 ns
15 32 47 0.003
12 32 37 0.01
5 33 15 ns
18 35 51 ns
10 31 32 0.04
32 33 97 0.002
5 12 42 ns
20 25 80 ns
20 24 83 ns
0 4 0 ns
3 15 20 0.05
16 17 94
larger denominator for the class 1 medication takes into account those with no records
CG) T-wave inversion, septal Q waves, poor R-wave progression in V1, V2, and V3,
17). ¶Echocardiogram: 112% Left ventricular dilatation (54), any right ventricular
nitor,1000 PVCs in 24 h, documented runs of VT of4 beats (17,60). **Magnetic
). ††Cardiac catheterization: any critical coronary artery disease. ‡‡Autopsy: evidenceof A
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February 1, 2005:400–8 ICD Improves Survival in Homogeneous ARVCeart transplant; the remaining 35 subjects died. The
ve-year mortality rate for males after ICD therapy was 0
ompared to 28% in controls (p  0.009) (Fig 3A).
The female ICD group (n  18) was followed for a
edian of 0.7 years, from 2 weeks to 3.9 years, and the
ontrol group (n  22) for a median of 28.8 years, from 1.9
ears to 37.8 years. There were no deaths in the ICD group,
hereas in the control group, 10 of 22 (45%) subjects had
ied. The five-year mortality rate in the control group was
%, which was not significantly different from that in the
emales who received an ICD (Fig. 3B).
ime to appropriate first discharge of the ICD. In the
ale ICD group (n  30), 14 subjects (47%) had at least
ne appropriate discharge for VT. The median time to first
igure 3. (A) Time to death or last follow-up (censored) in 30 male
ubjects at high-risk for arrhythmogenic right ventricular cardiomyopathy
inked to 3p25 who received implantable cardioverter-defibrillators (ICDs)
nd 36 matched control subjects. (B) Time to death or last follow-up
censored) in 18 female subjects at high risk for arrhythmogenic right
entricular cardiomyopathy linked to 3p25 who received ICDs and 22
atched control subjects.ischarge was 2.9 years (95% CI 1.17 to 4.6 years; range, 2 neeks to 5.1 years). The five-year cumulative frequency for
rst appropriate ICD discharge was 70%, which was signif-
cantly greater than the five-year mortality rate for the
ontrol group (p  0.0005). However, the five-year mor-
ality in the control group was similar to the five-year
umulative rate of 28% for VT 240 beats/min in the ICD
roup (Fig. 4). Two (11%) of 18 female ICD subjects had
n appropriate first discharge, both for VT240 beats/min.
We compared discharge for VT in males based on
hether the ICD was for primary or secondary indications.
o significant difference existed between the groups (me-
ian time 2.5 years, 95% CI 0 to 5.2 years vs. 2.9 years, 95%
I 0 to 6 years, respectively). A similar observation was
ade when time to first discharge for VT 240 beats/min
as assessed (results not shown). No significant difference in
ischarge in those with or without LVE was observed. In 16
ubjects with LVE, 45% had fired within five years, and in
0 subjects without LVE, all had fired. With respect to side
ffects observed, 5 (10%) of the 48 ICD subjects have had
ingle inappropriate shocks, and 3 had lead fracture, requir-
ng replacement.
ISCUSSION
ortality. The results of this study, from a large geneti-
ally homogenous population, demonstrate that ARVC,
hich is caused by an unknown mutation at the ARVD5
ocus on chromosome 3, is a life-shortening disorder. There
s a significantly increased relative risk of earlier death in
en compared with women, in agreement with previous
tudies (25,65), although the mortality rates in the current
tudy are higher than those for other familial forms of
RVC (41).
Guidelines for the prophylactic use of ICD in ARVC are
igure 4. Time to first appropriate discharge or last follow-up (censored)
or sustained ventricular tachycardia (VT) and for VT 240 beats/min in
ales who received an implantable cardioverter-defibrillator and time to
eath or last follow-up (censored) in matched controls with arrhythmo-
enic right ventricular cardiomyopathy linked to 3p25.ot established (66). Most subjects in this study were
e
t
b
t
h
t
a
m
i
E
I
d
s
a
a
s
d
f
p
i
s
o
r
r
s
(
w
s
fi
(
r
d
b
T
w
d
s
d
fi
o
m
p
a
g
w
g
c
t
f
w
e
g
p
H
w
H
s
d
a
i
t
t
s
I
s
r
a
I
S
s
c
c
g
a
F
r
H
A
w
t
i
a
a
s
A
l
I
t
i
t
d
(
o
i
n
A
h
c
t
d
A
m
f
l
t
C
m
s
D
f
406 Hodgkinson et al. JACC Vol. 45, No. 3, 2005
ICD Improves Survival in Homogeneous ARVC February 1, 2005:400–8ssentially asymptomatic, presenting a dilemma with respect
o therapy application. The use of ICD was thus influenced
y the fact that the presenting symptom often was SCD and
he extensive family histories defined a malignant natural
istory. Clinical testing in subjects from ARVC families in
his study who were at an a priori 50% pedigree risk, and the
vailability of genetic haplotyping, allowed accurate deter-
ination of those at greatest risk, permitting prophylactic
mplantation of an ICD.
fficacy of ICD. Few studies have assessed the efficacy of
CD therapy in ARVC (9,46–49,67). The largest series to
ate (48) studied a multicenter group of 132 patients, a
maller study assessed mainly primary prophylaxis (49), and
single-center study (9) reported on 60 subjects with
dvanced disease. These studies of heterogenous ARVC
ubjects estimated ICD mortality benefit based on
ischarge-free survival. In contrast, the 11 large ARVC
amilies linked by a founder haplotype in this current study
rovided the etiologic homogeneity that facilitated the
dentification of a robust control group matched for HR
tatus, age, gender, and family. As a result, a closer estimate
f the true magnitude of ICD therapy could be derived. The
esults clearly demonstrated that ICD therapy significantly
educed mortality in HR men from the ARVC families
tudied. Interestingly, these ICD mortality benefit results
28% five-year total mortality reduction in males compared
ith familial controls) appear similar to those in previous
tudies where discharge-free survival was estimated: 36%
ve-year total reduction (9) and 28% three-year reduction
48). Few side effects of ICD therapy occurred, and all were
esolved. It is notable that decreased mortality was observed
espite the fact that most men studied received an ICD
efore the documented onset of ventricular arrhythmias.
he results for women were not statistically significant,
hich was likely attributable to the reduced statistical power
ue to the less-malignant course of ARVC in women, the
maller sample size, and shorter duration of follow-up.
Theoretically, first ICD discharge would be analogous to
eath given certain criteria: that the ICD is programmed to
re at only those times when a potentially lethal arrhythmia
ccurs and that the insertion of the ICD is not proarrhyth-
ic (68), the latter being very unlikely given previous
rimary prevention studies (69). By the end of this study,
pproximately half of the male group and 10% of the female
roup had had an appropriate ICD discharge. However, it
as demonstrated that time to first discharge in the ICD
roup occurred much earlier than death occurred in the
ontrol group. There are several potential explanations for
his finding. First, subjects with ICDs may have progressed
urther in the disease process than the controls and thus
ere at greater risk of having an arrhythmic event. If this
xplanation were correct, then the benefit of ICD may be
reater than it would appear in this study. Against this
ossibility, however, is that the degree of ectopy observed on
M was similar in the ICD and control groups, and there
ere fewer ICD subjects with an abnormal echocardiogram. towever, the conclusion that ICD and control groups were
imilar should be tempered by the fact that the course of
isease in the control group was determined retrospectively,
nd data on clinical manifestations of disease were missing
n a substantial minority of controls. Finally, individuals in
he control group may have survived runs of VT, which
riggered discharge in the ICD group. This explanation
eems the most likely, given that we found that time to first
CD discharge for sustained VT 240 beats/min was
imilar to time to death in the control group. Unlike one
ecent study of ICD efficacy in ARVC (48), we did not find
relationship between LVE and rate of discharge of the
CD.
tudy limitations. There are several limitations to this
tudy. First, it is a cohort study with historic matched
ontrols. Second, there was selection bias in the choice of
ases for the ICD group and to a lesser extent the control
roup. Third, clinical data from the control group and from
minority of the ICD group were collected retrospectively.
inally, only families linked to 3p25 were studied, and the
esults may not be generalizable to all families with ARVC.
owever, a randomized controlled trial is not possible in
RVC, and all previous studies have been descriptive,
ithout an appropriate control group. The control group for
his study was matched for multiple factors that may
nfluence outcome: ARVC risk status, family, sex, gender,
nd survival. Selection bias was limited by including all
vailable controls and by studying only well ascertained
ibships in which50% of siblings at 50% risk had a known
RVC status. Furthermore, selection bias in the cases was
ikely to limit the effect size of the ICD as some cases had
CD because they had already developed VT and may
herefore have been more severely affected. However, these
ndividuals did not seem to have ICD discharge more often
han other subjects. The retrospective nature of the study
id not influence the determination of the primary outcome
mortality) but did limit the conclusions that could be drawn
n the comparability of the clinical manifestations of disease
n the ICD and control groups. Although these results may
ot be generalizable to other causes of ARVC, this
RVD5-linked population is by far the largest genetically
omogeneous group of ARVC subjects studied, and ARVC
aused by this mutation may be prevalent in other popula-
ions. Careful family history will detect an autosomal-
ominant mode of inheritance consistent with this form of
RVC, but positive family histories can be missed if the
utation is transmitted through several generations of
emales. Further studies will be necessary to determine the
ong-term clinical course of ARVC after ICD therapy and
o assess the utility of ICD in females with ARVC.
onclusions. We conclude that this form of ARVC is a
alignant disease, particularly in males, who frequently die
uddenly in early adulthood. The study is unique in that
NA haplotyping and extensive family history data are used
or risk stratification and subsequent prophylactic ICD
herapy in a large genetically homogeneous sample. Our
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February 1, 2005:400–8 ICD Improves Survival in Homogeneous ARVCesults demonstrate that this genetic risk stratification
odel for ICD therapy has a beneficial impact on survival in
ales in this population regardless of indication (primary or
econdary therapy), implying that SCD may be the first
ymptom in those at high risk. These results support the use
f ICDs as a primary prevention therapy in familial ARVC
inked to 3p25 for individuals at high genetic risk.
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